Advanced search
Publication Cover
Expert Review of Endocrinology & Metabolism Volume 8, 2013 - Issue 4
Submit an article Journal homepage
183
Views
37
CrossRef citations to date
0
Altmetric
Review

The FGF/FGF receptor axis as a therapeutic target in breast cancer

Nicholas J Brady Microbiology, Immunology and Cancer Biology Graduate Program, University of Minnesota, 420 Delaware St. SE, MMC 609, Minneapolis, MN 55455, USA; Microbiology, Immunology and Cancer Biology Graduate Program, University of Minnesota, 420 Delaware St. SE, MMC 609, Minneapolis, MN 55455, USA
,
Pavlina Chuntova Microbiology, Immunology and Cancer Biology Graduate Program, University of Minnesota, 420 Delaware St. SE, MMC 609, Minneapolis, MN 55455, USA; Microbiology, Immunology and Cancer Biology Graduate Program, University of Minnesota, 420 Delaware St. SE, MMC 609, Minneapolis, MN 55455, USA
,
Lindsey K Bade Molecular, Cellular, Developmental Biology and Genetics Graduate Program, University of Minnesota, 420 Delaware St. SE, MMC 609, Minneapolis, MN 55455, USA; Molecular, Cellular, Developmental Biology and Genetics Graduate Program, University of Minnesota, 420 Delaware St. SE, MMC 609, Minneapolis, MN 55455, USA
&
Kathryn L Schwertfeger Department of Laboratory Medicine and Pathology, University of Minnesota, 420 Delaware St. SE, MMC 609, Minneapolis, MN 55455, USA. [email protected]; Masonic Cancer Center, University of Minnesota, 420 Delaware St. SE, MMC 609, Minneapolis, MN 55455, USA; Department of Laboratory Medicine and Pathology, University of Minnesota, 420 Delaware St. SE, MMC 609, Minneapolis, MN 55455, USA. [email protected]; Masonic Cancer Center, University of Minnesota, 420 Delaware St. SE, MMC 609, Minneapolis, MN 55455, USA
Pages 391-402 | Published online: 10 Jan 2014

References

  • Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 16(2), 139–149 (2005).
  • Schlessinger J, Plotnikov AN, Ibrahimi OA et al. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol. Cell 6(3), 743–750 (2000).
  • Kan M, Wang F, Xu J, Crabb JW, Hou J, McKeehan WL. An essential heparin-binding domain in the fibroblast growth factor receptor kinase. Science 259(5103), 1918–1921 (1993).
  • Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol. 2(3), reviews3005 (2001).
  • Dieci MV, Arnedos M, Andre F, Soria JC. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov. 3(3), 264–279 (2013).
  • Haugsten EM, Wiedlocha A, Olsnes S, Wesche J. Roles of fibroblast growth factor receptors in carcinogenesis. Mol. Cancer Res. 8(11), 1439–1452 (2010).
  • Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer 10(2), 116–129 (2010).
  • Katoh M. FGFR2 abnormalities underlie a spectrum of bone, skin, and cancer pathologies. J. Invest. Dermatol. 129(8), 1861–1867 (2009).
  • Rutland P, Pulleyn LJ, Reardon W et al. Identical mutations in the FGFR2 gene cause both Pfeiffer and Crouzon syndrome phenotypes. Nat. Genet. 9(2), 173–176 (1995).
  • Bellusci S, Grindley J, Emoto H, Itoh N, Hogan BL. Fibroblast growth factor 10 (FGF10) and branching morphogenesis in the embryonic mouse lung. Development 124(23), 4867–4878 (1997).
  • Dillon C, Spencer-Dene B, Dickson C. A crucial role for fibroblast growth factor signaling in embryonic mammary gland development. J. Mammary Gland Biol. Neoplasia 9(2), 207–215 (2004).
  • Metzger RJ, Krasnow MA. Genetic control of branching morphogenesis. Science 284(5420), 1635–1639 (1999).
  • Schwertfeger KL. Fibroblast growth factors in development and cancer: insights from the mammary and prostate glands. Curr. Drug Targets 10(7), 632–644 (2009).
  • Vogel A, Rodriguez C, Izpisúa-Belmonte JC. Involvement of FGF-8 in initiation, outgrowth and patterning of the vertebrate limb. Development 122(6), 1737–1750 (1996).
  • Auguste P, Javerzat S, Bikfalvi A. Regulation of vascular development by fibroblast growth factors. Cell Tissue Res. 314(1), 157–166 (2003).
  • Veltmaat JM, Mailleux AA, Thiery JP, Bellusci S. Mouse embryonic mammogenesis as a model for the molecular regulation of pattern formation. Differentiation 71(1), 1–17 (2003).
  • Mailleux AA, Spencer-Dene B, Dillon C et al. Role of FGF10/FGFR2b signaling during mammary gland development in the mouse embryo. Development 129(1), 53–60 (2002).
  • Lu P, Ewald AJ, Martin GR, Werb Z. Genetic mosaic analysis reveals FGF receptor 2 function in terminal end buds during mammary gland branching morphogenesis. Dev. Biol. 321(1), 77–87 (2008).
  • Pond AC, Bin X, Batts T, Roarty K, Hilsenbeck S, Rosen JM. Fibroblast growth factor receptor signaling is essential for normal mammary gland development and stem cell function. Stem Cells 31(1), 178–189 (2013).
  • Adnane J, Gaudray P, Dionne CA et al. BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. Oncogene 6(4), 659–663 (1991).
  • Hynes NE, Dey JH. Potential for targeting the fibroblast growth factor receptors in breast cancer. Cancer Res. 70(13), 5199–5202 (2010).
  • Wesche J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in cancer. Biochem. J. 437(2), 199–213 (2011).
  • Gelsi-Boyer V, Orsetti B, Cervera N et al. Comprehensive profiling of 8p11-12 amplification in breast cancer. Mol. Cancer Res. 3(12), 655–667 (2005).
  • Letessier A, Sircoulomb F, Ginestier C et al. Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer 6, 245 (2006).
  • Elbauomy Elsheikh S, Green AR, Lambros MB et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res. 9(2), R23 (2007).
  • Garcia MJ, Pole JC, Chin SF et al. A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes. Oncogene 24(33), 5235–5245 (2005).
  • Turner N, Pearson A, Sharpe R et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 70(5), 2085–2094 (2010).
  • Tannheimer SL, Rehemtulla A, Ethier SP. Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE. Breast Cancer Res. 2(4), 311–320 (2000).
  • Heiskanen M, Kononen J, Bärlund M et al. CGH, cDNA and tissue microarray analyses implicate FGFR2 amplification in a small subset of breast tumors. Anal. Cell. Pathol. 22(4), 229–234 (2001).
  • Moffa AB, Tannheimer SL, Ethier SP. Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells. Mol. Cancer Res. 2(11), 643–652 (2004).
  • Katoh M. WNT and FGF gene clusters (review). Int. J. Oncol. 21(6), 1269–1273 (2002).
  • Wilkerson PM, Reis-Filho JS. The 11q13-q14 amplicon: clinicopathological correlations and potential drivers. Genes. Chromosomes Cancer 52(4), 333–355 (2013).
  • Stacey SN, Manolescu A, Sulem P et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet. 40(6), 703–706 (2008).
  • Sharpe R, Pearson A, Herrera-Abreu MT et al. FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clin. Cancer Res. 17(16), 5275–5286 (2011).
  • Tanaka A, Furuya A, Yamasaki M et al. High frequency of fibroblast growth factor (FGF) 8 expression in clinical prostate cancers and breast tissues, immunohistochemically demonstrated by a newly established neutralizing monoclonal antibody against FGF 8. Cancer Res. 58(10), 2053–2056 (1998).
  • Marsh SK, Bansal GS, Zammit C et al. Increased expression of fibroblast growth factor 8 in human breast cancer. Oncogene 18(4), 1053–1060 (1999).
  • Fillmore CM, Gupta PB, Rudnick JA et al. Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling. Proc. Natl Acad. Sci. USA 107(50), 21737–21742 (2010).
  • Hunter DJ, Kraft P, Jacobs KB et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet. 39(7), 870–874 (2007).
  • Easton DF, Pooley KA, Dunning AM et al.; SEARCH collaborators; kConFab; AOCS Management Group. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447(7148), 1087–1093 (2007).
  • Meyer KB, Maia AT, O’Reilly M et al. Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol. 6(5), e108 (2008).
  • Huijts PE, van Dongen M, de Goeij MC et al. Allele-specific regulation of FGFR2 expression is cell type-dependent and may increase breast cancer risk through a paracrine stimulus involving FGF10. Breast Cancer Res. 13(4), R72 (2011).
  • Ding L, Getz G, Wheeler DA et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455(7216), 1069–1075 (2008).
  • Marks JL, McLellan MD, Zakowski MF et al. Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. PLoS ONE 2(5), e426 (2007).
  • Jackson CC, Medeiros LJ, Miranda RN. 8p11 myeloproliferative syndrome: a review. Hum. Pathol. 41(4), 461–476 (2010).
  • Wu YM, Su F, Kalyana-Sundaram S et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 3, 636–647(2013).
  • Stephens P, Edkins S, Davies H et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat. Genet. 37(6), 590–592 (2005).
  • Reintjes N, Li Y, Becker A, Rohmann E, Schmutzler R, Wollnik B. Activating somatic FGFR2 mutations in breast cancer. PLoS ONE 8(3), e60264 (2013).
  • Holland DG, Burleigh A, Git A et al. ZNF703 is a common luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium. EMBO Mol. Med. 3(3), 167–180 (2011).
  • Hudis CA. Trastuzumab – mechanism of action and use in clinical practice. N. Engl. J. Med. 357(1), 39–51 (2007).
  • Jordan VC, Brodie AM. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 72(1), 7–25 (2007).
  • Choueiri TK, Alemany CA, Abou-Jawde RM, Budd GT. Role of aromatase inhibitors in the treatment of breast cancer. Clin. Ther. 26(8), 1199–1214 (2004).
  • Rodler E, Korde L, Gralow J. Current treatment options in triple negative breast cancer. Breast Dis. 32(1–2), 99–122 (2010).
  • Lehmann BD, Bauer JA, Chen X et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121(7), 2750–2767 (2011).
  • The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490(7418), 61–70 (2012).
  • Perou CM, Sørlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 406(6797), 747–752 (2000).
  • Prat A, Parker JS, Karginova O et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 12(5), R68 (2010).
  • Sørlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98(19), 10869–10874 (2001).
  • Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100(14), 8418–8423 (2003).
  • Azuma K, Tsurutani J, Sakai K et al. Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure. Biochem. Biophys. Res. Commun. 407(1), 219–224 (2011).
  • Issa A, Gill JW, Heideman MR et al. Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models. Breast Cancer Res. 15(1), R8 (2013).
  • Tomlinson DC, Knowles MA, Speirs V. Mechanisms of FGFR3 actions in endocrine resistant breast cancer. Int. J. Cancer 130(12), 2857–2866 (2012).
  • Nilsson EM, Brokken LJ, Narvi E, Kallio MJ, Härkönen PL. Identification of fibroblast growth factor-8b target genes associated with early and late cell cycle events in breast cancer cells. Mol. Cell. Endocrinol. 358(1), 104–115 (2012).
  • Bade LK, Goldberg JE, Dehut HA, Hall MK, Schwertfeger KL. Mammary tumorigenesis induced by fibroblast growth factor receptor 1 requires activation of the epidermal growth factor receptor. J. Cell. Sci. 124(Pt 18), 3106–3117 (2011).
  • Schwertfeger KL, Xian W, Kaplan AM, Burnett SH, Cohen DA, Rosen JM. A critical role for the inflammatory response in a mouse model of preneoplastic progression. Cancer Res. 66(11), 5676–5685 (2006).
  • Xian W, Schwertfeger KL, Rosen JM. Distinct roles of fibroblast growth factor receptor 1 and 2 in regulating cell survival and epithelial–mesenchymal transition. Mol. Endocrinol. 21(4), 987–1000 (2007).
  • Tarkkonen KM, Nilsson EM, Kähkönen TE et al. Differential roles of fibroblast growth factor receptors (FGFR) 1, 2 and 3 in the regulation of S115 breast cancer cell growth. PLoS ONE 7(11), e49970 (2012).
  • Chioni AM, Grose R. FGFR1 cleavage and nuclear translocation regulates breast cancer cell behavior. J. Cell Biol. 197(6), 801–817 (2012).
  • Cerliani JP, Guillardoy T, Giulianelli S et al. Interaction between FGFR-2, STAT5, and progesterone receptors in breast cancer. Cancer Res. 71(10), 3720–3731 (2011).
  • Welm BE, Freeman KW, Chen M, Contreras A, Spencer DM, Rosen JM. Inducible dimerization of FGFR1: development of a mouse model to analyze progressive transformation of the mammary gland. J. Cell Biol. 157(4), 703–714 (2002).
  • Pond AC, Herschkowitz JI, Schwertfeger KL et al. Fibroblast growth factor receptor signaling dramatically accelerates tumorigenesis and enhances oncoprotein translation in the mouse mammary tumor virus-Wnt-1 mouse model of breast cancer. Cancer Res. 70(12), 4868–4879 (2010).
  • Kao S, Mo J, Baird A, Eliceiri BP. Basic fibroblast growth factor in an animal model of spontaneous mammary tumor progression. Oncol. Rep. 27(6), 1807–1814 (2012).
  • Dey JH, Bianchi F, Voshol J, Bonenfant D, Oakeley EJ, Hynes NE. Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res. 70(10), 4151–4162 (2010).
  • Dirkx AE, Oude Egbrink MG, Wagstaff J, Griffioen AW. Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J. Leukoc. Biol. 80(6), 1183–1196 (2006).
  • Giulianelli S, Cerliani JP, Lamb CA et al. Carcinoma-associated fibroblasts activate progesterone receptors and induce hormone independent mammary tumor growth: A role for the FGF-2/FGFR-2 axis. Int. J. Cancer 123(11), 2518–2531 (2008).
  • Reed JR, Stone MD, Beadnell TC, Ryu Y, Griffin TJ, Schwertfeger KL. Fibroblast growth factor receptor 1 activation in mammary tumor cells promotes macrophage recruitment in a CX3CL1-dependent manner. PLoS ONE 7(9), e45877 (2012).
  • Bohrer LR, Schwertfeger KL. Macrophages promote fibroblast growth factor receptor-driven tumor cell migration and invasion in a CXCR2-dependent manner. Mol. Cancer Res. 10(10), 1294–1305 (2012).
  • Larrieu-Lahargue F, Welm AL, Bouchecareilh M et al. Blocking fibroblast growth factor receptor signaling inhibits tumor growth, lymphangiogenesis, and metastasis. PLoS ONE 7(6), e39540 (2012).
  • Guagnano V, Furet P, Spanka C et al. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J. Med. Chem. 54(20), 7066–7083 (2011).
  • Guagnano V, Kauffmann A, Wöhrle S et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2(12), 1118–1133 (2012).
  • Gavine PR, Mooney L, Kilgour E et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 72(8), 2045–2056 (2012).
  • Bello E, Taraboletti G, Colella G et al. The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts. Mol. Cancer Ther. 12(2), 131–140 (2013).
  • Gozgit JM, Wong MJ, Moran L et al. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol. Cancer Ther. 11(3), 690–699 (2012).
  • Bai A, Meetze K, Vo NY et al. GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. Cancer Res. 70(19), 7630–7639 (2010).
  • Sun HD, Malabunga M, Tonra JR et al. Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys. Am. J. Physiol. Endocrinol. Metab. 292(3), E964–E976 (2007).
  • Camozzi M, Rusnati M, Bugatti A et al. Identification of an antiangiogenic FGF2-binding site in the N terminus of the soluble pattern recognition receptor PTX3. J. Biol. Chem. 281(32), 22605–22613 (2006).
  • Leali D, Alessi P, Coltrini D et al. Long pentraxin-3 inhibits FGF8b-dependent angiogenesis and growth of steroid hormone-regulated tumors. Mol. Cancer Ther. 10(9), 1600–1610 (2011).
  • Rusnati M, Camozzi M, Moroni E et al. Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. Blood 104(1), 92–99 (2004).
  • Harding TC, Long L, Palencia S et al. Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits Growth of multiple types of cancer. Sci. Transl. Med. 5(178), 178ra39 (2013).
  • Gozgit JM, Squillace RM, Wongchenko MJ et al. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. Cancer Chemother. Pharmacol. 71(5), 1315–1323 (2013).
  • Martin LA, André F, Campone M, Bachelot T, Jerusalem G. mTOR inhibitors in advanced breast cancer: Ready for prime time? Cancer Treat. Rev. doi:10.1016/j.ctrv.2013.02.005 (2013).
  • Welti JC, Gourlaouen M, Powles T et al. Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene 30(10), 1183–1193 (2011).
  • Kang J, Lee SY, Lee SY et al. miRNA-99b acts as a tumor suppressor in non-small cell lung cancer by directly targeting fibroblast growth factor receptor 3. Exp. Ther. Med. 3(1), 149–153 (2012).
  • Rebustini IT, Hayashi T, Reynolds AD, Dillard ML, Carpenter EM, Hoffman MP. miR-200c regulates FGFR-dependent epithelial proliferation via Vldlr during submandibular gland branching morphogenesis. Development 139(1), 191–202 (2012).
  • Winter SF, Acevedo VD, Gangula RD, Freeman KW, Spencer DM, Greenberg NM. Conditional activation of FGFR1 in the prostate epithelium induces angiogenesis with concomitant differential regulation of Ang-1 and Ang-2. Oncogene 26(34), 4897–4907 (2007).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.